Clinical Trials Oversight: China released an updated Good Clinical Practice for Drugs guideline, adding data governance rules and clearer roles for investigators and sponsors; it takes effect Sept 1. Neurotechnology in Healthcare: China approved the first commercial brain-computer chip (NEO) for clinical sale, targeting spinal cord injury and paralysis, as Neuralink still awaits FDA clearance. Pharma Manufacturing Capacity: Novo Nordisk will invest 200 million yuan to expand its Tianjin hub, boosting drug manufacturing and injection pen assembly for growing demand. Gut Health Research: A Frontiers in Nutrition study links higher diet quality with lower insulin resistance and better lipid markers, with systemic inflammation partly explaining the association. Public Health & Food Safety: China’s regulator summoned Walmart over repeated food safety breaches, signaling tighter enforcement on supply-chain risk. Health System Integrity: Hong Kong’s ICAC charged a former senior staff member at the Chinese University Medical Centre over alleged fraud involving false patient service claims. Supply Chain & Health Tech: China is also pushing a massive homegrown AI data center buildout (2 trillion yuan over five years), aiming to reduce reliance on U.S. hardware—an indirect driver for future health AI infrastructure.